{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T21:59:10Z","timestamp":1783461550631,"version":"3.55.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Cancer-related anorexia-cachexia comprises one of the most common syndromes of advanced cancer patients. The management of cancer-related anorexia-cachexia is a great challenge in clinical practice. There are no definite practice guidelines yet for the prevention and treatment of cancer-related anorexia-cachexia. This study is considered to find out whether there is any role of mirtazapine in the improvement of anorexia in cancer patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 80 cancer-anorexia patients were enrolled. Patients in the trial arm received the standard chemotherapy medication plus one tablet of mirtazapine 15\u00a0mg daily at night orally for 8\u00a0weeks starting from the day of an initial assessment. The control arm received the standard chemotherapy medication plus one tablet of megestrol acetate 160\u00a0mg daily orally for 8\u00a0weeks starting from the day of an initial assessment. Each patient was assessed by validated versions of Functional Assessment of Anorexia\/Cachexia Therapy Anorexia\/Cachexia Sub Scale v 4 questionnaires.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After 4 and 8\u00a0weeks each patient was evaluated again using the Functional Assessment of Anorexia\/Cachexia Therapy Anorexia\/Cachexia Sub Scale tool. The quality of life of each patient was assessed by European Organization for Research and Treatment QLQ-C30 v 3.0. After 4 to 8\u00a0weeks of treatment, the Functional Assessment of Anorexia\/Cachexia Therapy Anorexia\/Cachexia Sub Scale score in cancer anorexia patients in the mirtazapine improved anorexia significantly. However, the improvement after 4 to 8\u00a0weeks was not statistically significant when it was compared with the megestrol acetate (P\u00a0&amp;gt;\u00a00.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Therefore, the findings of this study reveal that mirtazapine might be a potential alternative to megestrol acetate, as it has shown potential efficacy as like as megestrol acetate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae009","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T11:16:38Z","timestamp":1707304598000},"page":"530-536","source":"Crossref","is-referenced-by-count":11,"title":["Mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients: a randomized, double-blind trial"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7741-0311","authenticated-orcid":false,"given":"Iftekhar Hossain","family":"Chowdhury","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Mugda Medical College , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Sayedur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Najmul Kabir","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Dhaka College , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeasmin Jahan","family":"Afroze","sequence":"additional","affiliation":[{"name":"Department of Facio-Maxillary Surgical Oncology, National Institute of Cancer Research & Hospital , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuma","family":"Tabassum","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Dhaka Medical College , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Marnush","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Zerin","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Shaheed Suhrawardy Medical College , Dhaka , Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"2024050715015989200_ref1","volume-title":"Cancer","author":"World Health Organization","year":"2022"},{"key":"2024050715015989200_ref2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","article-title":"The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers","volume":"157","author":"Dyba","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024050715015989200_ref3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jpainsymman.2021.05.017","article-title":"Mirtazapine in cancer-associated anorexia and cachexia: a double-blind placebo-controlled randomized trial","volume":"62","author":"Hunter","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"2024050715015989200_ref4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","article-title":"Cachexia: pathophysiology and clinical relevance","volume":"83","author":"Morley","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"2024050715015989200_ref5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jcsm.12059","article-title":"Pathophysiology of anorexia in the cancer cachexia syndrome","volume":"6","author":"Ezeoke","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2024050715015989200_ref6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/1568026611109060609","article-title":"The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications","volume":"11","author":"Brett Lloyd","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"2024050715015989200_ref7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clnu.2013.01.004","article-title":"A new look at an old drug for the treatment of cancer cachexia: megestrol acetate","volume":"32","author":"Argil\u00e9s","year":"2013","journal-title":"Clin Nutr"},{"key":"2024050715015989200_ref8","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.3390\/cancers15143588","article-title":"Mirtazapine versus megestrol in the treatment of anorexia\u2013cachexia syndrome in patients with advanced cancer: a randomized, double-blind, controlled phase II clinical trial","volume":"15","author":"Almeida","year":"2023","journal-title":"Cancer"},{"key":"2024050715015989200_ref9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024050715015989200_ref10","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.ctarc.2021.100336","article-title":"Appetite problem in cancer patients: pathophysiology, diagnosis, and treatment","volume":"27","author":"Hariyanto","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"2024050715015989200_ref11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/1049909109345685","article-title":"Phase II trial of mirtazapine for cancer-related cachexia and anorexia","volume":"27","author":"Riechelmann","year":"2010","journal-title":"Am J Hosp Palliat Med"},{"key":"2024050715015989200_ref12","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1097\/00007632-200012150-00014","article-title":"Guidelines for the process of cross-cultural adaptation of self-report measures","volume":"25","author":"Beaton","year":"2000","journal-title":"Spine"},{"key":"2024050715015989200_ref13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143588","article-title":"Mirtazapine versus megestrol in the treatment of anorexia\u2013cachexia syndrome in patients with advanced cancer: a randomized, double-blind, controlled phase ii clinical trial","volume":"15","author":"Almeida","year":"2023","journal-title":"Cancers"},{"key":"2024050715015989200_ref14","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00520-019-05229-7","article-title":"What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review","volume":"28","author":"Economos","year":"2020","journal-title":"Support Care Cancer"},{"key":"2024050715015989200_ref15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0885-3924(02)00381-0","article-title":"An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms","volume":"23","author":"Theobald","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"2024050715015989200_ref16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/jrcr.jrcr_33_21","article-title":"Megestrol acetate in cancer cachexia and anorexia: tertiary care experience","volume":"12","author":"Fatima","year":"2021","journal-title":"J Radiat Cancer Res"},{"key":"2024050715015989200_ref17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0959-8049(98)00398-0","article-title":"Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial","volume":"35","author":"Westman","year":"1999","journal-title":"Eur J Cancer"},{"key":"2024050715015989200_ref18","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1200\/JCO.2000.18.15.2930","article-title":"On appetite and its loss","volume":"18","author":"Jatoi","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2024050715015989200_ref19","first-page":"227","article-title":"Palliative treatment of cancer anorexia with oral suspension of megestrol acetate","volume":"50","author":"Tomiska","year":"2003","journal-title":"Neoplasma"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/5\/530\/57434891\/hyae009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/5\/530\/57434891\/hyae009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:15:33Z","timestamp":1715094933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/5\/530\/7601772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,6]]},"published-print":{"date-parts":[[2024,5,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae009","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,2,6]]}}}